Your browser doesn't support javascript.
loading
An Initial Evaluation of Human Plasma cMLC-1: A Potential Protein Biomarker for Trastuzumab-Induced Cardiotoxicity, Breast Cancer Screening and Progression.
Yu, Ling; Allen, Read; Jia, Lin; Sun, Ting; Isakoff, Steven J; Scherrer-Crosbie, Marielle; Kehlmann, Allison M; Zheng, Hui; Ly, Amy; Walmsley, Charlotte S; Hesler, Katherine; Varasteh, Ava N; Pinto, Christopher J; McLoughlin, Daniel E; Wu, Wenjin; Wang, Xinhui.
Afiliação
  • Yu L; Division of Gastrointestinal and Oncologic Surgery, Department of Surgery, Massachusetts General Hospital, Harvard Medical School, Boston, MA, United States.
  • Allen R; Key Laboratory of Luminescence Analysis and Molecular Sensing, Ministry of Education, School of Materials and Energy, Southwest University, Chongqing, China.
  • Jia L; Termeer Center for Targeted Therapies, Massachusetts General Hospital Cancer Center, Boston, MA, United States.
  • Sun T; Division of Gastrointestinal and Oncologic Surgery, Department of Surgery, Massachusetts General Hospital, Harvard Medical School, Boston, MA, United States.
  • Isakoff SJ; Division of Gastrointestinal and Oncologic Surgery, Department of Surgery, Massachusetts General Hospital, Harvard Medical School, Boston, MA, United States.
  • Scherrer-Crosbie M; Termeer Center for Targeted Therapies, Massachusetts General Hospital Cancer Center, Boston, MA, United States.
  • Kehlmann AM; Perelman Center for Advanced Medicine, Cardiovascular Medicine Division, The Hospital of the University of Pennsylvania, Philadelphia, PA, United States.
  • Zheng H; Termeer Center for Targeted Therapies, Massachusetts General Hospital Cancer Center, Boston, MA, United States.
  • Ly A; Biostatistics Center, Massachusetts General Hospital, Harvard Medical School, Boston, MA, United States.
  • Walmsley CS; Department of Pathology, Massachusetts General Hospital, Harvard Medical School, Boston, MA, United States.
  • Hesler K; Termeer Center for Targeted Therapies, Massachusetts General Hospital Cancer Center, Boston, MA, United States.
  • Varasteh AN; Termeer Center for Targeted Therapies, Massachusetts General Hospital Cancer Center, Boston, MA, United States.
  • Pinto CJ; Termeer Center for Targeted Therapies, Massachusetts General Hospital Cancer Center, Boston, MA, United States.
  • McLoughlin DE; Termeer Center for Targeted Therapies, Massachusetts General Hospital Cancer Center, Boston, MA, United States.
  • Wu W; Termeer Center for Targeted Therapies, Massachusetts General Hospital Cancer Center, Boston, MA, United States.
  • Wang X; Division of Monoclonal Antibodies, Office of Biotechnology Products, Office of Pharmaceutical Science, Center for Drug Evaluation and Research, U.S. Food and Drug Administration, Bethesda, MD, United States.
Front Oncol ; 12: 809715, 2022.
Article em En | MEDLINE | ID: mdl-35592673
Palavras-chave
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Tipo de estudo: Diagnostic_studies / Prognostic_studies / Screening_studies Idioma: En Ano de publicação: 2022 Tipo de documento: Article
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Tipo de estudo: Diagnostic_studies / Prognostic_studies / Screening_studies Idioma: En Ano de publicação: 2022 Tipo de documento: Article